<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To compare long-term efficacy and safety of initial combination therapy with nateglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> versus <z:chebi fb="0" ids="5441">glyburide</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: We conducted a randomized, multicenter, double-masked, 2-year study of 428 drug-na√Øve patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>Patients received 120 mg a.c. nateglinide or 1.25 mg q.d. <z:chebi fb="0" ids="5441">glyburide</z:chebi> plus 500 mg q.d </plain></SENT>
<SENT sid="3" pm="."><plain>open-label <z:chebi fb="0" ids="6801">metformin</z:chebi> for the initial 4 weeks </plain></SENT>
<SENT sid="4" pm="."><plain>During a subsequent 12-week titration period, <z:chebi fb="0" ids="5441">glyburide</z:chebi> and <z:chebi fb="0" ids="6801">metformin</z:chebi> were increased by 1.25- and 500-mg increments to maximum daily doses of 10 and 2,000 mg, respectively, if biweekly fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG) &gt; or = 6.7 mmol/l </plain></SENT>
<SENT sid="5" pm="."><plain>Nateglinide was not titrated </plain></SENT>
<SENT sid="6" pm="."><plain>Blinding was maintained by use of matching placebo for nateglinide and <z:chebi fb="0" ids="5441">glyburide</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>An 88-week monitoring period followed, during which HbA1c (A1C), FPG, and postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> excursions (PPGEs) during an oral <z:chebi fb="105" ids="17234">glucose</z:chebi> tolerance test were measured </plain></SENT>
<SENT sid="8" pm="."><plain>RESULTS: In nateglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi>-treated patients, mean A1C was 8.4% at baseline and 6.9% at week 104 </plain></SENT>
<SENT sid="9" pm="."><plain>In <z:chebi fb="0" ids="5441">glyburide</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi>-treated patients, mean A1C was 8.3% at baseline and 6.8% at week 104 (P &lt; 0.0001 vs. baseline for both treatments, NS between treatments) </plain></SENT>
<SENT sid="10" pm="."><plain>The deltaPPGE averaged -96 +/- 19 (P &lt; 0.0001) and -57 +/- 22 mmol.l(-1).min(-1) (P &lt; 0.05) in patients receiving nateglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="5441">glyburide</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi>, respectively, whereas deltaFPG was -1.6 +/- 0.2 (P &lt; 0.0001) and -2.4 +/- 0.2 mmol/l (P &lt; 0.0001) in patients receiving nateglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="5441">glyburide</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi>, respectively (P &lt; 0.01 between groups) </plain></SENT>
<SENT sid="11" pm="."><plain>Thus, the two treatments achieved similar efficacy with differential effects on FPG versus PPGE </plain></SENT>
<SENT sid="12" pm="."><plain><z:hpo ids='HP_0001943'>Hypoglycemia</z:hpo> occurred in 8.2 and 17.7% of patients receiving nateglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="5441">glyburide</z:chebi>/<z:chebi fb="0" ids="6801">metformin</z:chebi>, respectively </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSIONS: Similar good glycemic control can be maintained for 2 years with either treatment regimen, but nateglinide/<z:chebi fb="0" ids="6801">metformin</z:chebi> may represent a safer approach to initial combination therapy </plain></SENT>
</text></document>